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According to ancient Chinese medical literature and Korean history, ginseng has been used 
since around 2000 BCE. It has been regarded as a very precious medicinal plant, on par with 
poppy, aloe, and garlic, the use of which goes back to the same period in other parts of the 
world. It is not surprising that the name Panax—meaning “all healing” in Greek—has been 
applied to this plant, because it has been used to treat various diseases from ancient times, 
and is also recognized, especially in Asian countries, as a health supplement that can increase 
energy and instill a sense of well-being. To date, fourteen species belonging to the Panax 
genus have been identified, and three species are widely circulated on the global market: 
Panax ginseng C.A. Meyer, cultivated mainly in Korea and northeastern China; Panax 
quinquefolius L. (American ginseng), grown mainly in the Canadian provinces of Ontario and 
British Columbia and the American state of Wisconsin; and Panax notoginseng Burkill, 
found in southern China (1).  
 
History and use 
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P. ginseng is likely to have originated in Manchuria (now the northeast part of China) and in 
the ancient Three Kingdoms of Korea (2). The first description of ginseng in the history of 
traditional Chinese medicine appeared in the pre-Han era (BCE 33–48), over 2,000 years ago. 
In 1713, the Royal Society published a letter from Father Jartoux, a Jesuit missionary in 
China, containing a description of ginseng’s botany, habitat, and medicinal uses (3). P. 
quinquefolius was discovered by American settlers in the mid-1700’s in New England. This 
plant had long been used by the Native Americans, who valued the root for its curative 
powers and life-enhancing capabilities. Ginseng has purported use for the treatment of cancer, 
diabetes, and cardiovascular dysfunctions, as well as for cognitive enhancement with an 
apparently low rate of adverse effects. In combination with other materia medica, P. ginseng 
and P. notoginseng have been used in complex Chinese formulations for treating angina 
pectoris (4, 5).  
Processing, chemistry, and metabolism  
Most ginseng in today’s market is cultivated in the field for 4 to 6 years. Ginseng is classified 
into three types, depending on how it is processed after harvest: fresh ginseng (can be 
consumed in its fresh state), white ginseng (dried after peeling), and red ginseng, which 
requires special preparation skills, such as steaming and drying under specific conditions. 
Technology for the long-term storage of red ginseng was developed by pioneers in ginseng 
manufacture, securing the foundation for this form of the root. The process of steaming 
stabilizes the ginseng with regard to metabolism, and transforms the secondary metabolites 
into less polar phytosteroids that are thought to be both more active in the body and safer.  
The active ingredients in ginseng include ginsenosides and polysaccharides. Ginsenosides 
belong to the saponin family and are divided into 20(S)-panaxadiols and 20(S)-panaxatriols, 
depending on the dammarane skeleton and the number of hydroxyl groups that can be 
substituted with other groups (1). The biological activities of these phytosteroids have been 
studied intensively with regard to their structure-activity relationships. Asian ginseng 
typically contains six types of ginsenosides: panaxadiols (Rb1, Rb2, Rc, and Rd) and 
panaxtriols (Re and Rg1). In contrast, American ginseng contains high levels of Rb1, Rd, and 
Re (6, 7).  
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Ginsenosides are extensively metabolized in the gastrointestinal tract after oral administration 
(8), with sugar moieties being removed to generate the aglycones, 20(S)-protopanaxadiol 
(aPPD), and 20(S)-protopanaxatriol (aPPT), and the partially deglycosylated ginsenosides. 
Since most native ginsenosides are either poorly absorbed in the intestines or are quickly 
metabolized by deglycosylation, oxidation, and esterification in the intestine or the liver, they 
could be regarded as “pro-drugs.” Thus, understanding the pharmacokinetics and 
pharmacodynamics of native ginsenosides and their metabolites is critical for their clinical 
application. 
 
Standardization  
Currently, there are many ginseng products on the market and the quality control of these 
commodities is of paramount importance. Quality control of ginseng extracts and finished 
products is usually based on the determination of specific bioactive ginsenosides. Although 
the international standard ISO 17217-1:2014 specifies minimum requirements and test 
methods for ginseng seeds and seedlings (9), ginseng extract should also be standardized such 
that each batch contains an acceptable concentration range of active ingredients to guarantee 
quality and efficacy from product to product. Distinguishing between P. ginseng and P. 
quinquefolius, which have similar chemical and physical properties but seemingly different 
pharmacological activities, is a challenge. Recently, all known ginsenosides were identified 
by metabolomics using high-performance chromatography/mass spectrometry analysis, and 
this large data set was statistically analyzed. In a targeted analysis, ginsenoside Rf was 
confirmed as a chemical marker present in processed P. ginseng, but not in processed P. 
quinquefolius (10).  
 
Diverse pharmacological activities via multiple mechanisms 
Given the structural similarity between ginsenosides and steroid hormones, we hypothesized 
that ginsenosides function as receptor agonists, partial agonists, or antagonists depending on 
the microenvironment. As shown in Figure 1, ginsenosides act by binding to steroid hormone 
receptors, such as androgen, estrogen, and glucocorticoid receptors, to modulate gene 
expression (11–14). We have previously reported that the dominance of Rg1 leads to 
 4 
 
angiogenesis, whereas Rb1 exerts an opposing effect (15) through activation of glucocorticoid 
(16) and estrogen (17) receptors. In addition to their classic genomic effects, ginsenosides can 
also function through transcription-independent, nongenomic activation of signaling cascades, 
such as phosphoinositide 3-kinase/Akt, adenosine monophosphate-activated protein kinase, 
and calcium signaling that occurs outside the nucleus (18–23) (Figure 1). Ginsenosides are 
also implicated in ion channel regulation, including voltage-dependent and ligand-gated ion 
channels, for the control of cardiovascular function and hypertension (24–26). Recent 
developments have also revealed ginsenosides to be an important regulator of microRNAs 
(miRNAs) (27–30). Moreover, mRNA-like, noncoding RNAs were identified in ginseng, 
suggesting that it might exert a regulatory role through miRNAs and small interfering RNAs 
(siRNAs) (31). Whether these small RNAs could affect our body function awaits further 
investigation (32). A number of studies have demonstrated that ginsenosides, and especially 
their metabolites, interact with cytochrome P450 enzymes (CYPs) and adenosine 
triphosphate (ATP)-binding cassette transporters (ABC transporters, including breast cancer 
resistance protein, BCRP) (33–36). Given the fundamental roles of ABC transporters and 
CYPs in the absorption, transportation, and metabolism of nutrients, hormones, and 
environmental toxins, it is plausible that ginseng may exert its wide-ranging biological effects 
and health benefits by modulating the transportation and metabolism of vital substances in 
the human body (Figure 2). Intriguingly, aPPD and aPPT are BCRP inhibitors and therefore 
potential chemosensitizers (37). Ginseng root also contains acidic polysaccharides that 
appear to play important roles in immune modulation (38). In addition, ginseng 
polysaccharides have shown antifatigue (39, 40) and antidiabetic (41) effects. However, 
although numerous studies have been done in vitro and in vivo, very few clinical studies exist.  
 
Challenges and opportunities  
Despite playing an important role as a health supplement and medicine in East Asia for 
millennia, the clinical efficacy of ginseng remains to be established through stringent 
evidence-based validation. The synthesis of ginsenosides, including the backbone and its 
glycosylated derivatives, is extremely challenging. This bottleneck limits the development of 
 5 
 
ginsenosides as drug candidates. Thus, developing novel techniques for enriching bioactive 
components in ginseng should be a top priority. For example, selective transformation of 
ginsenosides by specific intestinal microbes may provide a new opportunity for drug 
discovery. It is also an exciting prospect to obtain the full genome sequence of ginseng root 
as a precursor to manipulating the biosynthesis of specific ginsenosides and realizing a 
“ginsenoside factory” (42–44). A high-throughput, multidisciplinary approach should be 
developed to bring new insights into the molecular actions of ginsenosides and how the 
multiple, distinct signaling networks that it impacts are interconnected. Finally, more robust 
clinical trials should be designed and implemented. Only good clinical outcomes can instill 
faith in patients and the general public with regard to products derived from this time-
honored treatment. 
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FIGURE LEGENDS 
 
FIGURE 1. Schematic representation of genomic and nongenomic actions by 
ginsenosides. Ginsenosides can act through genomic effects by binding to steroid hormone 
receptors, such as androgen receptors (AR), estrogen receptors (ER), and glucocorticoid 
receptors (GR), to modulate gene expression. On the other hand, nongenomic activities, such 
as phosphoinositide 3-kinase/Akt (PI3K/Akt), adenosine monophosphate-activated protein 
kinases (AMPKs), and endothelial nitric oxide synthases (eNOS) that occur outside the 
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nucleus can also be involved in the mechanisms of action (MOAs) of ginsenosides. 
Ginsenosides are also implicated in ion channel regulation that includes the nicotinic 
acetylcholine receptor that results in sodium ion (Na+) influx and the GABAA/glycine 
receptor that conducts chloride (Cl–) ions. In addition, ginsenosides can be a regulator of 
microRNAs (miRNAs) that modulate angiogenesis, apoptosis, cell proliferation, and 
differentiation. 
 
FIGURE 2. Metabolism of ginseng. Ginsenosides can be converted into their metabolites 
that may contribute the majority of bioactivities by regulating the transportation and 
metabolism of crucial substances in the human body. Metabolism mainly occurs in the 
intestine and the liver by adenosine triphosphate (ATP)-binding cassette transporters (ABC 
transporters), cytochrome P450 enzymes (CYPs), and others. 
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